The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.

Described herein are methods of treating COVID19 from a coronavirus infection, methods of treating a subject having a coronavirus infection, methods of improving a survival rate of a subject having a coronavirus infection, methods of determining prognosis of a subject having a coronavirus infection, methods of preventing or treating organ-dysfunction or multi-organ dysfunction or failure associated with a coronavirus infection, methods of combinational therapy for a subject having a coronavirus infection, methods of reducing microthrombi formation or low flow organ-ischemia associated with a coronavirus infection by administering a DEspR inhibitor.

The present invention provides certain improved formulations of proteins. Specifically, the present invention provides use of certain excipients that are useful for stabilization of antibody preparations. Additionally, the novel formulation of the present invention prevents the formation of aggregates or fragments or modification of protein in solution.

Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.

Methods to measure free IL-17 in a sample comprising IL-17 and a small molecule modulator of IL-17.

The present application relates to novel prodrugs of IL-12. Further included in the present application are methods of making and using the novel prodrugs.

A method for determining a prognosis of idiopathic pulmonary fibrosis, comprising the following steps (a) to (c): (a) a step of detecting an amount of at least one protein selected from S100A4, CIRP, and 14-3-3γ for a biological sample separated from the test subject; (b) a step of comparing the amount of the protein detected in the step (a) with a standard amount of the protein; and (c) a step of determining that the prognosis of idiopathic pulmonary fibrosis of the test subject is poor in a case where as a result of the comparison in the step (b), the amount of the protein in the test subject is higher than the standard amount.

A method for determining a prognosis of idiopathic pulmonary fibrosis, comprising the following steps (a) to (c): (a) a step of detecting an amount of at least one protein selected from S100A4, CIRP, and 14-3-3γ for a biological sample separated from the test subject; (b) a step of comparing the amount of the protein detected in the step (a) with a standard amount of the protein; and (c) a step of determining that the prognosis of idiopathic pulmonary fibrosis of the test subject is poor in a case where as a result of the comparison in the step (b), the amount of the protein in the test subject is higher than the standard amount.

The invention provides novel CCL14 antibodies useful in evaluation of renal injuries. In a broad aspect, the present invention provides antibodies which bind CCL14. The provided antibodies can find use in assays to detect CCL14, such as immunoassays with improved clinical performance. In one aspect, the CCL14 antibodies are used in therapeutic methods in which CCL14 binding is desired.

The invention provides novel CCL14 antibodies useful in evaluation of renal injuries. In a broad aspect, the present invention provides antibodies which bind CCL14. The provided antibodies can find use in assays to detect CCL14, such as immunoassays with improved clinical performance. In one aspect, the CCL14 antibodies are used in therapeutic methods in which CCL14 binding is desired.